Cargando…

Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors

BACKGROUND: The impact of donor age on the immune reconstitution of patients with hematological malignancies who underwent hematopoietic cell transplantation (HCT) is unclear. METHOD: We retrospectively compared the outcomes of 381 patients who underwent allogeneic peripheral blood stem cell transpl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Peiyao, Cai, Yu, Zhou, Xiao, Yang, Jun, Tong, Yin, Huang, Chongmei, Qiu, Huiying, Zhou, Kun, Xu, Xiaowei, Zhang, Ying, Niu, Jiahua, Shen, Chang, Xia, Xinxin, Wei, Yu, Song, Xianmin, Wan, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078254/
https://www.ncbi.nlm.nih.gov/pubmed/36318732
http://dx.doi.org/10.1111/ctr.14844
_version_ 1785020477313384448
author Jiang, Peiyao
Cai, Yu
Zhou, Xiao
Yang, Jun
Tong, Yin
Huang, Chongmei
Qiu, Huiying
Zhou, Kun
Xu, Xiaowei
Zhang, Ying
Niu, Jiahua
Shen, Chang
Xia, Xinxin
Wei, Yu
Song, Xianmin
Wan, Liping
author_facet Jiang, Peiyao
Cai, Yu
Zhou, Xiao
Yang, Jun
Tong, Yin
Huang, Chongmei
Qiu, Huiying
Zhou, Kun
Xu, Xiaowei
Zhang, Ying
Niu, Jiahua
Shen, Chang
Xia, Xinxin
Wei, Yu
Song, Xianmin
Wan, Liping
author_sort Jiang, Peiyao
collection PubMed
description BACKGROUND: The impact of donor age on the immune reconstitution of patients with hematological malignancies who underwent hematopoietic cell transplantation (HCT) is unclear. METHOD: We retrospectively compared the outcomes of 381 patients who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from 308 donors under 50 years of age and 73 donors over 50 years of age. IVIG was regularly supplemented for patients in the first 3 months post‐HCT. RESULTS: The counts of CD8+CD45RA+ naïve T cells were significantly lower in patients of the older donor group than in the younger donor group in the first year after PBSCT (190.6 cells/μl vs. 239.6 cells/μl, p = .018). Patients in the older donor group had significantly fewer CD19+ B cells on day +270 (123.4 cells/μl vs. 183.5 cells/μl, p = .021) and day +365 (169 cells/μl vs. 271.1 cells/μl, p = .01) after PBSCT. Serum IgA (.76 g/L vs. .97 g/L, p < .001) and IgM levels (.75 g/L vs. 1.04 g/L, p < .001) were significantly lower in patients in the older donor group from day +60 to +365 after PBSCT. The EBV reactivation rate within the first 3 months after PBSCT was significantly higher in patients in the older donor group (48.6% vs. 38.3%, p = .034). However, the incidences of CMV reactivation, II‐IV acute graft‐versus‐host disease (aGvHD), chronic GvHD (cGvHD), 3‐year relapse rate, 3‐year transplant‐related mortality (TRM) and 3‐year overall survival (OS) were not significantly different between the two groups. CONCLUSION: In conclusion, donors ≥50 years old were associated with inferior immune reconstitution and higher EBV reactivation in patients after PBSCT, but no change in OS.
format Online
Article
Text
id pubmed-10078254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100782542023-04-07 Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors Jiang, Peiyao Cai, Yu Zhou, Xiao Yang, Jun Tong, Yin Huang, Chongmei Qiu, Huiying Zhou, Kun Xu, Xiaowei Zhang, Ying Niu, Jiahua Shen, Chang Xia, Xinxin Wei, Yu Song, Xianmin Wan, Liping Clin Transplant Original Articles BACKGROUND: The impact of donor age on the immune reconstitution of patients with hematological malignancies who underwent hematopoietic cell transplantation (HCT) is unclear. METHOD: We retrospectively compared the outcomes of 381 patients who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from 308 donors under 50 years of age and 73 donors over 50 years of age. IVIG was regularly supplemented for patients in the first 3 months post‐HCT. RESULTS: The counts of CD8+CD45RA+ naïve T cells were significantly lower in patients of the older donor group than in the younger donor group in the first year after PBSCT (190.6 cells/μl vs. 239.6 cells/μl, p = .018). Patients in the older donor group had significantly fewer CD19+ B cells on day +270 (123.4 cells/μl vs. 183.5 cells/μl, p = .021) and day +365 (169 cells/μl vs. 271.1 cells/μl, p = .01) after PBSCT. Serum IgA (.76 g/L vs. .97 g/L, p < .001) and IgM levels (.75 g/L vs. 1.04 g/L, p < .001) were significantly lower in patients in the older donor group from day +60 to +365 after PBSCT. The EBV reactivation rate within the first 3 months after PBSCT was significantly higher in patients in the older donor group (48.6% vs. 38.3%, p = .034). However, the incidences of CMV reactivation, II‐IV acute graft‐versus‐host disease (aGvHD), chronic GvHD (cGvHD), 3‐year relapse rate, 3‐year transplant‐related mortality (TRM) and 3‐year overall survival (OS) were not significantly different between the two groups. CONCLUSION: In conclusion, donors ≥50 years old were associated with inferior immune reconstitution and higher EBV reactivation in patients after PBSCT, but no change in OS. John Wiley and Sons Inc. 2022-11-14 2023-01 /pmc/articles/PMC10078254/ /pubmed/36318732 http://dx.doi.org/10.1111/ctr.14844 Text en © 2022 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Jiang, Peiyao
Cai, Yu
Zhou, Xiao
Yang, Jun
Tong, Yin
Huang, Chongmei
Qiu, Huiying
Zhou, Kun
Xu, Xiaowei
Zhang, Ying
Niu, Jiahua
Shen, Chang
Xia, Xinxin
Wei, Yu
Song, Xianmin
Wan, Liping
Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title_full Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title_fullStr Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title_full_unstemmed Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title_short Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
title_sort immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078254/
https://www.ncbi.nlm.nih.gov/pubmed/36318732
http://dx.doi.org/10.1111/ctr.14844
work_keys_str_mv AT jiangpeiyao immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT caiyu immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT zhouxiao immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT yangjun immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT tongyin immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT huangchongmei immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT qiuhuiying immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT zhoukun immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT xuxiaowei immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT zhangying immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT niujiahua immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT shenchang immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT xiaxinxin immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT weiyu immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT songxianmin immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors
AT wanliping immunereconstitutionandsurvivalofpatientsafterallogeneichematopoieticstemcelltransplantationfromolderdonors